However, low molecular weight fucoidan will only be accepted by consumers and regulatory agencies if efficacy for certain well defined diseases like [HBx,src], [HBx,src,p53−/+], and CD36‐related HCC has been established using randomized controlled trials, and if severe adverse effects had not been observed, providing thereby a favorable profile of benefits over risks.61 This evidence concerns the gene TP53 and hepatocellular carcinoma.